Genetic and Epigenetic Alteration in Gastric Carcinogenesis

Helicobacter

Volumn 15, Issue SUPPL. 1, 2010, Pages 34-39

  Resende, Carlos ^a,b   Ristimäki, Ari ^c   Machado, José C ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Experimental models; Molecular alterations; Single nucleotide polymorphism

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BUB1 RELATED PROTEIN; CABECITAPIN; CISPLATIN; DNA METHYLTRANSFERASE 3A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; KRUPPEL LIKE FACTOR 6; LAPATINIB; MYC PROTEIN; PROSTATE STEM CELL ANTIGEN; TRATUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; XRCC1 PROTEIN;

ARTICLE; BCL2L12 GENE; BUBR1 GENE; CANCER COMBINATION CHEMOTHERAPY; CLDN11 GENE; EPIGENETICS; GASTROINTESTINAL CARCINOMA; GENE; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; NONHUMAN; PRIORITY JOURNAL; RBP2 GENE; RELN GENE; SEMA5A GENE; SFRP5 GENE; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS;

CARCINOMA; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HELICOBACTER INFECTIONS; HUMANS; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS;

EID: 78249282604     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00782.x     Document Type: Article

References (61)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2002;55:74-108.
2. Vogiatzi P, Vindigni C, Roviello F, Renieri A, Giordano A. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol 2007;211:287-95.
3. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354-62.
4. Yin M, Hu Z, Tan D, Ajani JA, Wei Q. Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. Am J Transl Res 2009;1:44-54.
5. Shikata K, Doy Y, Yonemoto K, et al. Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence: the Hisayama study. Am J Epidemiol 2008;12:1409-15.
6. Machado JC, Figueiredo C, Canedo P, et al. A proinflamatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003;2:364-71.
7. Canedo P, Corso G, Pereira F, et al. The interferon gamma receptor 1 (IFNGR1) -56C/T gene polymorphism is associated with increased risk of early gastric carcinoma. Gut 2008;11:1504-8.
8. Canedo P, Duraes C, Pereira F, et al. Tumour necrosis factor alpha extended haplotypes and risk of colorectal and gastric carcinoma. Cancer Epidemiol Biomarkers Prev 2008;17:2416-20.
9. Pinheiro H, Bordeira-Carriço R, Seixas S, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 2010;5:943-52.
10. Milne AN, Carneiro F, O'Morain C, Offerhaus GJ. Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 2009;126:615-28.
11. Fan H, Liu D, Qiu X, et al. A functional polymorphism in the DNA methyltransferase-3A promoter modifies the susceptibility in gastric cancer but not in esophageal carcinoma. BMC Med 2010;8:12.
12. Samuel MS, Suzuki H, Buchert M, et al. Elevated Dnmt3a activity promotes polyposis in Apc Min mice by relaxing extracellular restrains on Wnt signaling. Gastroenterology 2009;137:902-13.
13. Ding WJ, Fang JY, Chen XY, Peng YS. The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer. Dig Dis Sci 2008;53:2083-9.
14. Ju H, Lim B, Kim M, et al. A regulatory polymorphism at position -309 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression. Neoplasia 2009;11:1340-7.
15. Motoya S, Kitamura K, Matsuda A, Maizel AL, Yamamoto H, Takeda A. Interaction between CD45-AP and protein-tyrosine kinases involved in T cell receptor signaling. J Biol Chem 1999;274:14392-9.
16. Avizienyte E, Wyke AW, Jones RJ, et al. SRC-induced de-regulation of E-cadherin in colon cancer cells requires integrin signaling. Nat Cell Biol 2002;4:632-8.
17. Sakamoto H, Yoshimura K, Saeki N, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008;40:730-40.
18. Lu Y, Chen J, Ding Y, et al. Genetic variation of PSCA gene is associated with the risk of both diffuse and intestinal-type gastric cancer in a Chinese population. Int J Cancer 2010;Feb 3. [Epub ahead of print].
19. Ke Q, Liang J, Wang LN, et al. Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer. Mol Carcinog 2008;47:647-51.
20. Zhao R, Liu XQ, Wu XP, et al. Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha (v) beta6. Cancer Lett 2010;287:150-6.
21. Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol 2009;9:77.
22. Tahara T, Shibata T, Nakamura M, et al. Effect of polymorphisms in the 3, untranslated region (3,-UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan. Mol Carcinog 2009;48:1030-7.
23. Caldecott KW, Tucker JD, Stanker LH, Thompson LH. Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells. Nucleic Acids Res 1995;23:4836-43.
24. Hao B, Miao X, Li Y, et al. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene 2006;25:3613-20.
25. Corso G, Marrelli D, Pedrazzani C, et al. Gastric cardia carcinoma is associated with the promoter -77T>C gene polymorphism of X-ray cross-complementing group 1 (XRCC1). J Gastrointest Surg 2009;13:2233-8.
26. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumours of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
27. Kozma L, Kiss I, Hajdu J, Szentkereszty Z, Szakall S, Ember I. C-myc amplification and cluster analysis in human gastric carcinoma. Anticancer Res 2001;21:707-10.
28. Pan G, Lv Hui, Ren H, et al. Elevated expression of semaphoring 5A in human gastric cancer and its implication in carcinogenesis. Life Sci 2010;86:139-44.
29. Florou D, Papadopoulos IN, Scorilas A. Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. Biochem Biophys Res Commun 2010;391:214-8.
30. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007;447:407-12.
31. Zeng J, Ge Z, Wang L, et al. The histone demethylase RBP2 is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology 2010;138:981-92.
32. Buffart TE, Van Grieken NCT, Tijssen M, et al. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch 2009;455:213-23.
33. Van Deursen JM. Rb loss causes cancer by driving mitosis mad. Cancer Cell 2007;11:1-3.
34. Ando K, Kakeji Y, Kitao H, et al. High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. Cancer Sci 2010;101:639-45.
35. Sangodkar J, Shi J, DiFeo A, et al. Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer 2009;45:666-76.
36. Dohi O, Takada H, Wakabayashi N, et al. Epigenetic silencing of RELN in gastric cancer. Int J Oncol 2010;36:85-92.
37. Du P, Ye HR, Gao J, et al. Methylation of PTCH1a gene in a subset of gastric cancers. World J Gastroenterol 2009;15:3799-806.
38. Ye Q, Shen Y, Wang X, et al. Hypermethylation of HLC class I is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens 2010;75:30-9.
39. Agarwal R, Mori Y, Cheng Y, et al. Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells. PLoS ONE 2009;4:e8002.
40. Zhao C, Bu X, Zhang N, Wang W. Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MTI-MMP in gastric cancer. BMC Cancer 2009;9:224.
41. Regalo G, Resende C, Wen X, et al. C/EBPalpha expression is associated with homeostasis of the gastric epithelium and with gastric carcinogenesis. Lab Invest 2010;Apr 12. [Epub ahead of print].
42. Rhyu MG, Park WS, Meltzer SJ. Microssatelite instability occurs frequently in human gastric carcinoma. Oncogene 1994;1:29-32.
43. Carneiro F, Oliveira C, Leite M, Seruca R. Molecular targets and biological modifiers in gastric cancer. Semin Diagn Pathol 2008;4:274-87.
44. Velho S, Oliveira C, Paredes J, et al. Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Hum Mol Genet 2010;19:697-706.
45. Kang RM, Kim MS, Oh JE, et al. Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. J Pathol 2009;217:702-6.
46. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009;77:400-10.
47. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009;10:1179-87.
48. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-9.
49. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33.
50. Arrington AK, Dahlberg PS, Davydova J, Vickers SM, Yamamoto M. ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas. Surgery 2009;146:213-9.
51. Arrington AK, Davydova J, Vickers SM, Yamamoto M. Anti-ERBB2 sh-RNA suppress both cell growth and tumour growth in ERBB2-overexpressing upper gastrointestinal adenocarcinomas. J Gastrointest Surg 2009;13:1754-61.
52. Tanizaki J, Okamoto I, Takezawa K, et al. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 2010;9:1198-207.
53. LaBonte MJ, Manegold PC, Wilson PM, et al. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int J Cancer 2009;125:2957-69.
54. Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010;16:1509-19.
55. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
56. Kim JW, Hwang I, Kim MJ, Jang SJ. Clinicopathological characteristics and predictive markers of early gastric cancer with recurrence. J Korean Med Sci 2009;24:1158-64.
57. Barros-Silva JD, Leitão D, Afonso L, Vieira J, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009;100:487-93.
58. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010;32:57-65.
59. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-77.
60. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase Ill study of trastuzumab added to standard chemotherapy in frist-line human epidermal growth factor receptor 2 positive advanced gastric cancer. J Clin Oncol 2009;27: (suppl; abstr LBA4509).
61. Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009;27: (suppl; abstr 4556).